Learn the key differences between obstructive and nonobstructive HCM, including how your specific diagnosis can impact ...

Hypertrophic cardiomyopathy is an underdiagnosed genetic disorder, resulting from mutations in sarcomeric proteins. It has a highly variable clinical presentation, with some individuals remaining ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carolyn Ho, MD: ...

Camzyos, which works by blocking the actin-myosin interactions responsible for HCM and, in effect, relaxing the heart, bears ...

Please provide your email address to receive an email when new articles are posted on . Mavacamten (MyoKardia) is a novel, oral, allosteric modulator of cardiac myosin. This therapy was specifically ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy, the first ...

"Women come significantly later to their cardiologists and have the same peri-procedural [alcohol septal ablation] complications and worse long-term outcomes, which are caused by their older age; ...

Mavacamten is a selective, reversible, allosteric cardiac myosin inhibitor. It is approved under the brand name Camzyos ® for the treatment of adults with symptomatic New York Heart Association class ...

NEW HYDE PARK, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- CareMed (R) , an independent specialty pharmacy, has been selected as a pharmacy partner by Cytokinetics for MYQORZO (TM) (aficamten), indicated ...

"Older patients often tolerate medications poorly and younger patients may feel lethargic and tired with beta blockers and calcium channel blockers. These patients would be appropriate candidates for ...

BMS Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos in Adolescents with Symptomatic oHCM ...

Mavacamten, an investigational allosteric modulator of cardiac myosin, has proved superior to placebo for improving symptoms and reducing or eliminating obstruction of the left ventricle in patients ...